Alzheimer's disease (AD), the most common form of dementia, is a progressive and
multifactorial neurodegenerative disorder whose primary causes are mostly unknown. Due …

Nanomedicine is currently focused on the design and development of nanocarriers that
enhance drug delivery to the brain to address unmet clinical needs for treating …

Catechol-O-methyltransferase inhibitors (iCOMT), such as entacapone, have been
successfully employed to treat tremor-related symptoms of Parkinson's disease. However …

The blood-brain barrier (BBB) is a membrane barrier considered one of the most crucial
protective architectures in the central nervous system (CNS). Its presence acts as a hurdle …

Neurodegeneration is characterized by progressive neuronal loss in the brain impairing
normal brain functioning. Cognitive and motor deficits are common symptoms of …

This review explores the diverse applications of gold nanoparticles (AuNPs) in neurological
diseases, with a specific focus on Alzheimer's disease (AD), Parkinson's disease (PD), and …

Background Alzheimer's disease (AD) is characterized by neuroinflammation linked to
amyloid β (Aβ) aggregation and phosphorylated tau (τ) protein in neurofibrillary tangles …

Delivering drugs to the brain is a complex challenge in medical research, particularly for
disorders like Alzheimer's and Parkinson's. The blood–brain barrier restricts the entry of …

The development of paclitaxel-loaded polymeric nanoparticles for the treatment of brain
tumors was investigated. Poly (lactide-glycolide)(PLGA) nanoparticles containing 10% w/w …

Chemotherapy and surgery remain the primary treatment modalities for cancers; however,
these techniques have drawbacks, such as cancer recurrence and toxic side effects …